| Title |
Download |
| Formulation and Drug Delivery Assessment of Self-Association of Protein Therapeutics at High Concentration, A Very Non-ideal Situation - S.J. Shire, Genentech, Inc |
 |
| Analytical Methods for Biologics Comparability Strategy for Manufacturing Changes During the Development Phase - Dr. Achim Heinrich & Dr. Sven Oliver Arndt, Merck KGaA |
|
| Recovery and Purification The future of antibody purification - Duncan Low, Amgen, Inc |
|
| Scale-Up, Economics and Manufacturing Strategies Is Recombinant Manufacture of Peptides Economically Viable, Dr Friedrich Nachtmann, Sandoz GmbH |
|
| Cell Culture and Upstream Processing GMP Cell Banks, Points to consider for preparation, storage, transfers, release - Corinna Sonderegger, Sandoz |
|
| Prefills Emerge As a Major Growth Market, Vetter Pharma-Fertigung GmbH & Co. KG |
|
| Pilot to Production - Scaleable Powdered Media Manufacturing, Lonza |
|
| The Next Five Years and More, BioProcess International |
|
| A Bioassay Glossary - Robert Singer, David M. Lansky, and Walter W. Hauck |
|
| Investigation of Product Microheterogeneity - A Case Study in Rapid Detection of Mutation in Mammalian Production Cell Lines |
|
| Criteria for Selection of IgG Isotype and Glycoform of Antibody Therapeutics - Royston Jefferis |
|
| Impact of Cell Density and Viability on Primary Clarification of Mammalian Cell Broth - An Analysis Using Disc-Stack Centrifugation and Charged Depth Filtration |
|
| Animal-Free Cell Culture Ingredients for Optimal Performance - Dermot Pearson, PhD |
|
| Applying Rapid Microbiological Methods to Biologics Manufacture - An Overview of Current Industry Practice - Bettina Grosse, Robert Johnson, and Ulrich Herber |
|
| Demonstrating Comparability for Well-Characterised Biotechnology Products - Early Phase, Late Phase and Post Approval - John Towns & Keith Webber |
|
| No Slowdown in Cell Line Development |
|
| Cell Culture & Upstream Processing - BioProcess International Article Resources |
|
| List of Companies in Attendance so far |
|
